

# David W Cescon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2912210/publications.pdf>

Version: 2024-02-01

96  
papers

8,480  
citations

101496

36  
h-index

48277

88  
g-index

98  
all docs

98  
docs citations

98  
times ranked

13418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA - Journal of the American Medical Association, 2003, 289, 2801.	3.8	1,188
2	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, The, 2020, 396, 1817-1828.	6.3	992
3	Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nature Genetics, 2004, 36, 471-475.	9.4	749
4	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell, 2015, 27, 211-222.	7.7	748
5	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 397-404.	0.6	538
6	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 405-411.	0.6	419
7	Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 2020, 1, 276-290.	5.7	309
8	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Experimental Medicine, 2013, 210, 1529-1544.	4.2	239
9	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell, 2016, 30, 337-348.	7.7	166
10	Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent. Cancer Cell, 2014, 26, 163-176.	7.7	150
11	Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4326-4335.	3.3	137
12	Evolution of the Randomized Controlled Trial in Oncology Over Three Decades. Journal of Clinical Oncology, 2008, 26, 5458-5464.	0.8	136
13	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	2.3	132
14	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nature Communications, 2020, 11, 4205.	5.8	130
15	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 31-39.	3.0	129
16	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2841-2846.	3.3	118
17	Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Annals of Oncology, 2017, 28, v608.	0.6	117
18	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes and Development, 2013, 27, 1101-1114.	2.7	113

#	ARTICLE	IF	CITATIONS
19	Targeting the cell cycle in breast cancer: towards the next phase. <i>Cell Cycle</i> , 2018, 17, 1871-1885.	1.3	108
20	Estrogen controls the survival of BRCA1-deficient cells via a PI3Kâ€NRF2-regulated pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4472-4477.	3.3	100
21	AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3604-3613.	3.3	96
22	MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. <i>Cancer Cell</i> , 2018, 34, 579-595.e8.	7.7	94
23	Epigenetic Switchâ€Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1312-1329.	7.7	84
24	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. <i>Nature Genetics</i> , 2016, 48, 1260-1266.	9.4	75
25	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. <i>Breast</i> , 2019, 48, 17-23.	0.9	73
26	Invasive Pulmonary Aspergillosis Associated With Marijuana Use in a Man With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2214-2215.	0.8	65
27	Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1913-1918.	3.3	64
28	Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1570-E1577.	3.3	62
29	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
30	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2017, 77, 40-47.	1.3	52
31	Benchmarking to the Gold Standard: Hyaluronanâ€Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture. <i>Advanced Materials</i> , 2019, 31, e1901166.	11.1	51
32	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e88238.	1.1	51
33	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2499-2505.	3.2	48
34	Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101085.	3.9	48
35	Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids. <i>Nature Communications</i> , 2022, 13, 1466.	5.8	48
36	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. <i>Nature Chemical Biology</i> , 2022, 18, 821-830.	3.9	43

#	ARTICLE	IF	CITATIONS
37	Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. <i>Nature Communications</i> , 2022, 13, .	5.8	43
38	<i>p53 Arg72Pro</i> and <i>MDM2 T309G</i> Polymorphisms, Histology, and Esophageal Cancer Prognosis. <i>Clinical Cancer Research</i> , 2009, 15, 3103-3109.	3.2	39
39	Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 296-304.	0.5	35
40	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2019, 121, 318-324.	2.9	35
41	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. <i>Cancer Research</i> , 2019, 79, 4539-4550.	0.4	34
42	LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. <i>Annals of Oncology</i> , 2021, 32, S1289-S1290.	0.6	33
43	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. <i>Clinical Cancer Research</i> , 2022, 28, 1680-1689.	3.2	32
44	Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings. <i>Journal of Clinical Oncology</i> , 2009, 27, 3938-3944.	0.8	28
45	Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. <i>Annals of Oncology</i> , 2010, 21, 1411-1418.	0.6	28
46	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	1.1	27
47	Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced <i>N</i>-glycosylation Abundance and Branching. <i>Cancer Research</i> , 2021, 81, 2625-2635.	0.4	24
48	W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy. <i>Molecular Genetics and Metabolism</i> , 2005, 84, 374-375.	0.5	21
49	Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1775-1786.	1.9	21
50	Barcoded Medication Administration. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2200.	3.8	19
51	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCT019041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	1.2	17
52	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 759-767.	1.1	16
53	DNA replication stress: a source of APOBEC3B expression in breast cancer. <i>Genome Biology</i> , 2016, 17, 202.	3.8	16
54	CD2BP1 and CARD15 Mutations Are Not Associated with Pyoderma Gangrenosum in Patients with Inflammatory Bowel Disease. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1054-1056.	0.3	15

#	ARTICLE	IF	CITATIONS
55	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
56	Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer. <i>Breast</i> , 2021, 58, 6-9.	0.9	15
57	Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning. <i>Cmaj</i> , 2009, 180, 251-251.	0.9	14
58	Breaking up Is Hard to Do: PI3K Isoforms on the Rebound. <i>Cancer Cell</i> , 2015, 27, 5-7.	7.7	14
59	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425.	1.1	14
60	Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 934-941.	1.0	13
61	Association of <i>MDM2</i> and <i>TG309G</i> and <i>p53</i> polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1482-1488.	1.4	12
62	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
63	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	1.3	11
64	MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with <sup>99m</sup> Tc(l) Tricarbonyl Complex. <i>Molecular Pharmaceutics</i> , 2019, 16, 3559-3568.	2.3	10
65	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 257-267.	1.1	10
66	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 138-143.	3.4	9
67	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 676-685.	0.4	9
68	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. <i>Journal of Cancer</i> , 2021, 12, 4372-4378.	1.2	9
69	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2460-2470.	3.2	8
70	The Antiarrhythmic Drug, Dronedaron, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THR1±1) Antagonism. <i>Scientific Reports</i> , 2018, 8, 16562.	1.6	8
71	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 15-29.	1.1	8
72	Development of novel agents for the treatment of early estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 62, S34-S42.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103566.	2.0	8
74	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020, 6, 22.	2.3	7
75	Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors. <i>Cancer Research</i> , 2016, 76, CT066-CT066.	0.4	6
76	Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10810-E10811.	3.3	5
77	On the Road to Precision: Understanding the Biology Driving Genomic Assays. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-102.	0.8	5
78	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021, 13, eabf4969.	5.8	5
79	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	0.8	5
80	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 881-888.	2.9	5
81	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 539-545.	0.6	4
82	PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later. <i>Annals of Oncology</i> , 2021, 32, 1460-1462.	0.6	4
83	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 415-417.	5.1	3
84	Mutations in Noncoding <i>Cis</i> -Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 102-113.	1.5	3
85	19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC). <i>Annals of Oncology</i> , 2020, 31, S7.	0.6	2
86	43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia. <i>Annals of Oncology</i> , 2020, 31, S1257.	0.6	2
87	68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC. <i>Annals of Oncology</i> , 2020, 31, S1268.	0.6	2
88	356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009. <i>Annals of Oncology</i> , 2020, 31, S392.	0.6	1
89	531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial. <i>Annals of Oncology</i> , 2021, 32, S596.	0.6	1
90	KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, ix7-ix8.	0.6	1

#	ARTICLE	IF	CITATIONS
91	164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355. <i>Annals of Oncology</i> , 2022, 33, S197-S198.	0.6	1
92	Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2395-2397.	0.8	1
93	Gene Expression Analyses in Breast Cancer: Sample Matters. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky019.	1.4	0
94	Accelerating drug access from advanced to early breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 538-546.	1.1	0
95	Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2534-2534.	0.8	0
96	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7517-7517.	0.8	0